1. A method for modulating a disease or condition associated with phospholipase D (PLD) initiated polymorphoneutrophil (PMN) inflammation in a subject, comprising

administering to the subject an effective anti-inflammatory amount of a lipoxin analog having the formula



wherein X is R_1, OR_1, or SR_1;

wherein R_1 is

(i) a hydrogen atom;

(ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;

(iii) a cycloalkyl of 3 to 10 carbon atoms;

(iv) an aralkyl of 7 to 12 carbon atoms;

(v) phenyl;

(vi) substituted phenyl



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, $-CN$,

$-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;

(vii) a detectable label molecule; or

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=O), SO_2 or (CN), provided when Q_1 is CN, then X is absent;

wherein Q_3 and Q_4 are each independently O, S or NH;

wherein one of R_2 and R_3 is a hydrogen atom and the other is

(a) H;

(b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;

(c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;

(d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or

(e) $R_aQ_2R_b$ wherein Q_2 is $-O-$ or $-S-$; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R_4 is

(a) H;

(b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein R_5 is



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, $-CN$, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R_6 is

(a) H;

(b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof, such that a disease or condition associated with PLD initiated polymorphoneutrophil (PMN) inflammation in a subject is modulated.

2. The method of claim 1, wherein said method is performed *in vitro*.

3. The method of claim 1, wherein said method is performed *in vivo*.

4. A method for treating phospholipase D (PLD) initiated polymorphoneutrophil (PMN) inflammation in a subject, comprising

administering to the subject an effective anti-inflammatory amount of a lipoxin analog having the formula



wherein X is R_1, OR_1, or SR_1;

wherein R_1 is

(i) a hydrogen atom;

(ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;

(iii) a cycloalkyl of 3 to 10 carbon atoms;

(iv) an aralkyl of 7 to 12 carbon atoms;

(v) phenyl;

(vi) substituted phenyl



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, $-CN$, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to

8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;

(vii) a detectable label molecule; or

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=O), SO_2 or (CN), provided when Q_1 is CN, then X is absent;
wherein Q_3 and Q_4 are each independently O, S or NH;
wherein one of R_2 and R_3 is a hydrogen atom and the other is

(a) H;

(b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;

(c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;

(d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or

(e) $R_aQ_2R_b$ wherein Q_2 is -O- or -S-; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R_4 is

(a) H;

(b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein R_5 is



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, $-CN$, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R_6 is

(a) H;

(b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof, such that PLD initiated polymorphoneutrophil (PMN) inflammation is treated in a subject.

5. The method of claim 1, wherein said method is performed *in vitro*.

6. The method of claim 1, wherein said method is performed *in vivo*.

7. A method for modulating a disease or condition associated with phosphlipase D (PLD) initiated superoxide generation or degranulation activity in a subject, comprising

administering to the subject an effective anti-PLD amount of a lipoxin analog having the formula



wherein X is R_1, OR_1, or SR_1;

wherein R_1 is

(i) a hydrogen atom;

(ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;

(iii) a cycloalkyl of 3 to 10 carbon atoms;

(iv) an aralkyl of 7 to 12 carbon atoms;

(v) phenyl;

(vi) substituted phenyl



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, $-CN$,

$-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;

(vii) a detectable label molecule; or

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=O), SO_2 or (CN), provided when Q_1 is CN, then X is absent;
wherein Q_3 and Q_4 are each independently O, S or NH;
wherein one of R_2 and R_3 is a hydrogen atom and the other is

(a) H;

(b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;

(c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;

(d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or

(e) $R_aQ_2R_b$ wherein Q_2 is –O– or –S–; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R_4 is

(a) H;

(b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein R_5 is



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, $-CN$, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R_6 is

(a) H;

(b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof, such that a disease or condition associated with PLD initiated superoxide generation or degranulation activity in a subject is modulated.

8. The method of claim 7, wherein said method is performed *in vitro*.

9. The method of claim 7, wherein said method is performed *in vivo*.

10. A method for treating phospholipase D (PLD) initiated superoxide generation or degranulation in a subject, comprising

administering to the subject an effective anti-PLD amount of a lipoxin analog having the formula



wherein X is R_1, OR_1, or SR_1;

wherein R_1 is

(i) a hydrogen atom;

(ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;

(iii) a cycloalkyl of 3 to 10 carbon atoms;

(iv) an aralkyl of 7 to 12 carbon atoms;

(v) phenyl;

(vi) substituted phenyl



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, $-CN$, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to

8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;

(vii) a detectable label molecule; or

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=O), SO_2 or (CN), provided when Q_1 is CN, then X is absent;
wherein Q_3 and Q_4 are each independently O, S or NH;
wherein one of R_2 and R_3 is a hydrogen atom and the other is

(a) H;

(b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;

(c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;

(d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or

(e) $R_aQ_2R_b$ wherein Q_2 is –O– or –S–; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R_4 is

(a) H;

(b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein R_5 is



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, $-CN$, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R_6 is

(a) H;

(b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof, such that PLD initiated superoxide generation or granulation is treated in a subject.

11. The method of claim 10, wherein said method is performed *in vitro*.

12. The method of claim 10, wherein said method is performed *in vivo*.

13. A packaged pharmaceutical composition for treating a disease or condition associated with phospholipase D (PLD) initiated activity in a subject, comprising:

a container holding a therapeutically effective amount of at least one lipoxin compound having the formula



wherein X is R_1, OR_1, or SR_1;

wherein R_1 is

(i) a hydrogen atom;

(ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;

(iii) a cycloalkyl of 3 to 10 carbon atoms;

(iv) an aralkyl of 7 to 12 carbon atoms;

(v) phenyl;

(vi) substituted phenyl



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, $-CN$, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and

hydroxyl;

(vii) a detectable label molecule; or

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=O), SO_2 or (CN), provided when Q_1 is CN, then X is absent;
wherein Q_3 and Q_4 are each independently O, S or NH;
wherein one of R_2 and R_3 is a hydrogen atom and the other is

(a) H;

(b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;

(c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;

(d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or

(e) $R_aQ_2R_b$ wherein Q_2 is –O– or –S–; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R_4 is

(a) H;

(b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein R_5 is



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R_6 is

(a) H;

(b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof; and

instructions for using said lipoxin compound for treating a disease or condition associated with PLD initiated activity in the subject.

14. A packaged pharmaceutical composition for treating phospholipase D initiated activity in a subject, comprising:

a container holding a therapeutically effective amount of at least one lipoxin compound having the formula



wherein X is R_1, OR_1, or SR_1;

wherein R_1 is

(i) a hydrogen atom;

(ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;

(iii) a cycloalkyl of 3 to 10 carbon atoms;

(iv) an aralkyl of 7 to 12 carbon atoms;

(v) phenyl;

(vi) substituted phenyl



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to

8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;

(vii) a detectable label molecule; or

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=O), SO_2 or (CN), provided when Q_1 is CN, then X is absent;
wherein Q_3 and Q_4 are each independently O, S or NH;
wherein one of R_2 and R_3 is a hydrogen atom and the other is

(a) H;

(b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;

(c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;

(d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or

(e) $R_aQ_2R_b$ wherein Q_2 is -O- or -S-; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R_4 is

(a) H;

(b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein R_5 is



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, $-CN$, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R_6 is

(a) H;

(b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof; and

instructions for using said lipoxin compound for treating PLD initiated activity in the subject.

15. A packaged pharmaceutical composition for treating a disease or condition associated with phospholipase D (PLD) initiated superoxide generation or degranulation activity in a subject, comprising:

a container holding a therapeutically effective amount of at least one lipoxin compound having the formula



wherein X is R_1, OR_1, or SR_1;

wherein R_1 is

(i) a hydrogen atom;

(ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;

(iii) a cycloalkyl of 3 to 10 carbon atoms;

(iv) an aralkyl of 7 to 12 carbon atoms;

(v) phenyl;

(vi) substituted phenyl



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;

(vii) a detectable label molecule; or

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=O), SO_2 or (CN), provided when Q_1 is CN, then X is absent;
wherein Q_3 and Q_4 are each independently O, S or NH;
wherein one of R_2 and R_3 is a hydrogen atom and the other is

(a) H;

(b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;

(c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;

(d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or

(e) $R_aQ_2R_b$ wherein Q_2 is –O– or –S–; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R_4 is

(a) H;

(b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein R_5 is



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, $-CN$, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where $a+b=3$, $a=0$ to 3, $b=0$ to 3 and Z is cyano, nitro or a halogen;

wherein R_6 is

(a) H;

(b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof; and

instructions for using said lipoxin compound for treating a disease or condition associated with PLD initiated superoxide generation or degranulation activity in the subject.

16. A packaged pharmaceutical composition for treating phospholipase D (PLD) initiated superoxide generation or degranulation activity in a subject, comprising:

a container holding a therapeutically effective amount of at least one lipoxin compound having the formula



wherein X is R_1, OR_1, or SR_1;

wherein R_1 is

(i) a hydrogen atom;

(ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;

(iii) a cycloalkyl of 3 to 10 carbon atoms;

(iv) an aralkyl of 7 to 12 carbon atoms;

(v) phenyl;

(vi) substituted phenyl



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN,

$-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;

(vii) a detectable label molecule; or

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=O), SO_2 or (CN), provided when Q_1 is CN, then X is absent;
wherein Q_3 and Q_4 are each independently O, S or NH;
wherein one of R_2 and R_3 is a hydrogen atom and the other is

(a) H;

(b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;

(c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;

(d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or

(e) $R_aQ_2R_b$ wherein Q_2 is –O– or –S–; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R_4 is

(a) H;

(b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein R_5 is



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, $-CN$, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where $a+b=3$, $a=0$ to 3, $b=0$ to 3 and Z is cyano, nitro or a halogen;

wherein R_6 is

(a) H;

(b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof; and

instructions for using said lipoxin compound for treating PLD initiated superoxide generation or degranulation activity in the subject.